Design of a highly potent anti-hypertensive peptide based on ovokinin(2-7)

81Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Ovokinin(2-7) (RADHPF), an orally active anti-hypertensive peptide derived from ovalbumin, lowers blood pressure in SHRs at a dose of 10 mg/kg. Attempts were made to potentiate its anti-hypertensive activity by replacing the amino acid residues in [Pro2, Phe3]-ovokinin(2-7), which was previously reported to have 33-fold stronger activity than ovokinin(2-7). The anti-hypertensive activity of [Pro2, Phe3]-ovokinin(2-7) was improved by replacement of the C-terminal Phe residue with Trp. Then, the best amino acid residues at other positions for the anti-hypertensive effect were selected. RPLKPW, the most potent derivative obtained, showed significant anti-hypertensive activities at a dose of 0.1 mg/kg after oral administration in spontaneously hypertensive rats (SHRs). Thus, RPLKPW showed 100-fold more potent anti-hypertensive activity than ovokinin(2-7). © 2002 by Japan Society for Bioscience, Biotechnology, and Agrochemistry.

Cite

CITATION STYLE

APA

Yamada, Y., Matoba, N., Usui, H., Onishi, K., & Yoshikawa, M. (2002). Design of a highly potent anti-hypertensive peptide based on ovokinin(2-7). Bioscience, Biotechnology and Biochemistry, 66(6), 1213–1217. https://doi.org/10.1271/bbb.66.1213

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free